Welcome to our dedicated page for Modular Med news (Ticker: MODD), a resource for investors and traders seeking the latest updates and insights on Modular Med stock.
Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company focused on insulin delivery technology for people with diabetes. Its news flow centers on the design and development of user-friendly, affordable patch pumps, regulatory milestones for its Pivot tubeless insulin delivery system, and capital markets activity related to funding its operations.
Company announcements frequently highlight progress on the Pivot insulin delivery system, which Modular Medical describes as a next-generation, tubeless, removable three milliliter patch pump aimed at adult "almost-pumpers" who have not adopted traditional insulin pumps. News items include updates on Institutional Review Board (IRB) approvals for in-house studies, feasibility and insulin-use trials under simulated real-world conditions, and the submission of a 510(k) premarket filing to the U.S. Food and Drug Administration. The company also reports that the Pivot insulin delivery system is not currently cleared for sale by the FDA.
Investors following MODD news will also see disclosures about manufacturing readiness, such as validation of the Pivot controller manufacturing line for human-use production and steps toward high-volume manufacturing. Additional coverage includes progress toward CE Mark certification under EU MDR 2017/745, including ISO 13485:2016 quality management audits, as the company prepares for potential international commercialization.
Financial and listing-related updates form another important part of Modular Medical’s news stream. The company issues press releases on public offerings of common stock and warrants, warrant exercises and inducement agreements, and Nasdaq notices regarding minimum bid price compliance and related extensions. For those tracking MODD, this news page provides a centralized view of regulatory, operational, and financing developments affecting the company’s insulin delivery technology business.
Modular Medical (NASDAQ:MODD) will effect a 1-for-30 reverse stock split effective March 31, 2026 at 5:30am ET to increase its per-share trading price and meet Nasdaq's $1.00 minimum bid requirement. The company will trade on a split-adjusted basis under MODD with new CUSIP 60785L306.
Outstanding shares will be reduced from 139,810,797 pre-split to approximately 4,660,360 post-split. Fractional shares will be paid in cash. Equity awards and warrants will be adjusted (shares ÷30; exercise prices ×30). Shareholder approval occurred January 23, 2026; transfer agent Colonial Stock Transfer is the exchange agent.
Modular Medical (NASDAQ:MODD) priced a public offering of 68,098,000 common shares (or pre-funded warrants) and warrants to purchase up to 68,098,000 shares at a combined public offering price of $0.1762 per share and warrant.
The warrants are exercisable immediately, expire five years from issuance, and the offering is expected to generate approximately $12.0 million in gross proceeds before fees. Closing is expected on or about March 4, 2026, subject to customary closing conditions.
Modular Medical (NASDAQ:MODD) announced the start of validation production lots for its Pivot™ tubeless patch pump cartridge and infusion set, supporting a planned commercial launch in Q1 2026, subject to FDA 510(k) clearance. The Pivot is a removable, tubeless 3ml patch pump aimed at adults using multiple daily injections (MDI) to expand access with a lower-cost, user-friendly design. The company says scalable, low-cost manufacturing readiness derisks execution and positions Modular Medical to pursue share in the ~$8 billion insulin pump market as FDA review progresses. The Pivot system is not cleared for sale by the FDA.
Modular Medical (NASDAQ:MODD) said Nasdaq granted a 180-day extension to regain compliance with the minimum bid price rule, extending the cure period to June 29, 2026. The company must have a closing bid of $1.00 or more for 10 consecutive business days before that date to regain compliance. If compliance is not achieved during the extension, Nasdaq will notify the company that its common stock will be delisted, and the company may appeal to a hearings panel with no assurance of success. Nasdaq's notice does not affect current listing or trading, and the company says it will monitor the bid price and evaluate options to regain compliance.
Modular Medical (Nasdaq:MODD) priced an underwritten public offering of 12,173,000 common shares with accompanying warrants to purchase 6,086,500 shares.
Shares and warrants are sold in a 2-for-1 pairing at a combined public offering price of $0.77 (effective price $0.38 per share and $0.01 per warrant). Warrants carry a $0.45 exercise price and expire five years after issuance. The offering may include a 30-day underwriter option to buy up to an additional 15% of shares and/or warrants.
Assuming no over-allotment, gross proceeds are expected to be approximately $4.68 million; net proceeds will fund operations, working capital and capital expenditures. Closing is expected on or about December 11, 2025. The offering is being made from an SEC-effective Form S-3 shelf registration (File No. 333-287313).
Modular Medical (NASDAQ:MODD) announced on December 9, 2025 that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase common stock. The common shares and warrants will be issued separately but sold together in the offering. Modular Medical expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate shares and/or warrants. The offering is being made from an effective Form S-3 shelf registration (File No. 333-287313) declared effective by the SEC on May 22, 2025. Newbridge Securities Corporation is the sole bookrunner. The offering is subject to market conditions and may not be completed as proposed.
Modular Medical (NASDAQ:MODD) announced IRB approval on November 17, 2025 to run an in-house study delivering insulin with its next-generation Pivot™ tubeless patch pump to adult participants wearing continuous glucose monitors.
The Study will simulate real-world conditions to collect device function, usability data, and participant feedback while the company awaits FDA feedback on a recent Pivot 510(k) submission. The Pivot system is not currently cleared for sale by the FDA.
Modular Medical (NASDAQ:MODD) submitted its next-generation Pivot tubeless insulin patch pump for FDA 510(k) clearance on November 14, 2025 and expects to commence commercial launch in Q1 2026 upon clearance. The Pivot features a 3 ml removable reservoir, a two-part detachable design (removable for showering/activities) and bolus capability without a separate controller. Manufacturing conversion is validated and on track for launch readiness. The company noted an FDA submission delay due to the U.S. government shutdown and expects initial FDA questions in Q4 2025. The Pivot is not currently cleared for sale by the FDA.
Modular Medical (Nasdaq:MODD) announced successful validation of its Pivot controller line, a manufacturing milestone supporting planned Q1 2026 commercial launch for the Pivot tubeless, removable 3 milliliter patch pump. The company said the validated line demonstrates readiness for high-volume human-use production and aims to address a roughly $3 billion market for adult “almost-pumpers” with an affordable, easy-to-learn design. Modular Medical described the validation as derisking its path to commercial manufacturing, while noting Pivot is not currently cleared by the FDA and the launch remains subject to forward-looking risks.
Modular Medical (Nasdaq:MODD) reported progress toward CE Mark certification for its Pivot insulin delivery system, following successful completion of a Stage 1 ISO 13485:2016 audit by BSI with no major nonconformances identified.
The company plans a Stage 2 audit in early 2026, the final step before ISO 13485 certification, and will begin preparations for a CE technical documentation review anticipated later in 2026. Successful completion of these steps is required for Modular Medical's planned commercial launch in the EU.
The Pivot system is not currently cleared for sale by the U.S. FDA or in any market outside the U.S.